Free Trial
NASDAQ:ARDS

Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

Aridis Pharmaceuticals logo
$0.0001 +0.00 (+∞)
As of 07/15/2025 09:34 AM Eastern

About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.00
$0.07
Volume
2,950 shs
Average Volume
9,093 shs
Market Capitalization
$5.33 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARDS Stock News Headlines

Aridis Pharmaceuticals, Inc. (ARDS) - Yahoo Finance
Aridis Provides Corporate Update
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Aridis Provides Corporate Update
Aridis Pharmaceuticals Inc (ARDS)
See More Headlines

ARDS Stock Analysis - Frequently Asked Questions

Aridis Pharmaceuticals' stock was trading at $0.0001 at the start of the year. Since then, ARDS shares have increased by 0.0% and is now trading at $0.0001.

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $1.43. The firm had revenue of $0.52 million for the quarter.

Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aridis Pharmaceuticals investors own include VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dare Bioscience (DARE), BioCardia (BCDA), Moleculin Biotech (MBRX), SCYNEXIS (SCYX) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/10/2021
Today
7/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARDS
CIK
1614067
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
53,321,000
Free Float
50,388,000
Market Cap
$5.33 thousand
Optionable
Not Optionable
Beta
11.59
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ARDS) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners